Oral corticosteroids (OCS), inhaled corticosteroids (ICS), short acting β-2 agonists (SABA), ICS/long acting β-2 agonists (LABA) treatment in pregnancy with asthma: a review
Abstract
Asthma is one of the common pulmonary disorders that can complicate pregnancy. Therefore, managing asthma is crucial for pregnant women's health and the well-being of the embryo. As consequence, it is important to evaluate the effectiveness and integrity of treatment for this usual therapy in expectant mothers with asthma. This review aimed to analyze the efficacy and safety of OCS, ICS, SABA, and ICS/LABA treatment in pregnancy with asthma. The articles were researched from PubMed, Scopus, and Science Direct as literature resources and selection of process based on inclusion criteria. The use of OCS, ICS, SABA, ICS/LABA were safe for pregnancy with asthma, although there are some side effects. In conclusion, the regiment therapy of asthma in asmathic pregnant women is similar to general treatment for asthmatic.
References
Dombrowski MP, Schatz M, Wise R, Momirova V, Landon M, Mabie W, et al. Asthma during pregnancy. Obstet Gynecol 2004; 103(1):5-12. https://doi.org/10.1097/01.AOG.0000103994.75162.16
Murphy VE. Managing asthma in pregnancy. Breathe (Sheff) 2015; 11(4):258-67. https://doi.org/10.1183/20734735.007915
Australian Asthma Handbook [Internet]. [18 Oktober 2022]. https://www.asthmahandbook.org.au/
Namazy JA, Schatz M. The safety of asthma medications during pregnancy: an update for clinicians. Ther Adv Respir Dis 2014; 8(4):103-10. https://doi.org/10.1177/1753465814540029
Gregersen TL, Ulrik CS. Safety of bronchodilators and corticosteroids for asthma during pregnancy: what we know and what we need to do better. J Asthma Allergy 2013; 6:117-25. https://doi.org/10.2147/JAA.S52592
Palmsten K, Bandoli G, Vazquez-Benitez G, Xi M, Johnson DL, Xu R, et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatology (Oxford) 2020; 59(6):1262-71.
https://doi.org/10.1093/rheumatology/kez405
Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J 2014; 8:59-65.
https://doi.org/10.2174/1874306401408010059
Davies G, Jordan S, Thayer D, Tucker D, Humphreys I. Medicines prescribed for asthma, discontinuation and perinatal outcomes, including breastfeeding: A population cohort analysis. PLoS One. 2020 Dec 9;15(12):e0242489. doi: 10.1371/journal.pone.0242489.
Eltonsy S, Forget A, Beauchesne MF, Blais L. Risk of congenital malformations for asthmatic pregnant women using a long-acting β₂-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy. J Allergy Clin Immunol 2015; 135(1):123-30.
https://doi.org/10.1016/j.jaci.2014.07.051
Lim A, Hussainy SY, Abramson MJ. Asthma drugs in pregnancy and lactation. Australian Prescriber 2013; 36(5):150-3.
https://doi.org/10.18773/austprescr.2013.061
Robijn AL, Brew BK, Jensen ME, Rejnö G, Lundholm C, Murphy VE, Almqvist C. Effect of maternal asthma exacerbations on perinatal outcomes: a population-based study. ERJ Open Res. 2020 Dec 21;6(4):00295-2020
https://doi.org/10.1183/23120541.00295-2020
GINA. https://ginasthma.org/wp-content/uploads/2021/05/Whats-new-in-GINA-2021_final_V2.pdf
Barnes PJ. Asthma mechanisms. Medicine. 2016; 44(5): 65-270. https://doi.org/10.1016/j.mpmed.2016.02.020.
Zaidi S, Chen MJ, Lee DT, Neubart E, Ewing P, Miller-Larsson A, et al. Fetal concentrations of budesonide and fluticasone propionate: A study in mice. AAPS J 2019; 21(4):53.
https://doi.org/10.1208/s12248-019-0313-2
Eltonsy S, Forget A, Beauchesne MF, Blais L. Risk of congenital malformations for asthmatic pregnant women using a long-acting β2-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy. J Allergy Clin Immunol 2015;135(1): 123-30.e2.
https://doi.org/10.1016/j.jaci.2014.07.051.
Barisione G, Baroffio M, Crimi E, Brusasco V. Beta-adrenergic agonists. pharmaceuticals (Basel) 2010; 3(4):1016-44.
https://doi.org/10.3390/ph3041016
Shedd GC, Hays CN. The pregnant patient with asthma: Assessment and management. Journal Nurse Pract 2016; 12(1):1-6.
https://doi.org/10.1016/j.nurpra.2015.10.019
Cheng SL, Ho ML, Lai YF, Wang HC, Hsu JY, Liu SF, et al. Budesonide/formoterol anti-inflammatory reliever and maintenance or fluticasone propionate/salmeterol plus as-needed, short-acting β2 agonist: Real-world effectiveness in patients without optimally controlled asthma (REACT) study. Drug Des Devel Ther 2020; 14:5441-50.
https://doi.org/10.2147/DDDT.S266177
Mostafa MM, Rider CF, Wathugala ND, Leigh R, Giembycz MA, Newton R. Transcriptome-level interactions between budesonide and formoterol provide insight into the mechanism of action of inhaled corticosteroid/long-acting β 2-adrenoceptor agonist combination therapy in asthma. Mol Pharmacol 2021; 99(3):197-216.
https://doi.org/10.1124/molpharm.120.000146
Peterka M, Heringova LH, Sukop A, Peterkova R. Anti-asthma drugs formoterol and budesonide (Symbicort) induce orofacial clefts, gastroschisis and heart septum defects in an in vivo model. In Vivo 2021; 35(3):1451-60.
